Cargando…
Optimal anti-amyloid-beta therapy for Alzheimer’s disease via a personalized mathematical model
With the recent approval by the FDA of the first disease-modifying drug for Alzheimer’s Disease (AD), personalized medicine will be increasingly important for appropriate management and counseling of patients with AD and those at risk. The growing availability of clinical biomarker data and data-dri...
Autores principales: | Hao, Wenrui, Lenhart, Suzanne, Petrella, Jeffrey R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477429/ https://www.ncbi.nlm.nih.gov/pubmed/36054214 http://dx.doi.org/10.1371/journal.pcbi.1010481 |
Ejemplares similares
-
Data-driven causal model discovery and personalized prediction in Alzheimer's disease
por: Zheng, Haoyang, et al.
Publicado: (2022) -
Mathematical model on Alzheimer’s disease
por: Hao, Wenrui, et al.
Publicado: (2016) -
Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease
por: Petrella, Jeffrey R., et al.
Publicado: (2019) -
Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
por: Richard, Edo, et al.
Publicado: (2021) -
Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
por: Marr, Robert A., et al.
Publicado: (2014)